X4 Pharmaceuticals
Biotechnology company developing treatments for rare diseases and cancers by targeting the CXCR4 pathway, a critical regulator of immune cell trafficking. Publicly traded on NASDAQ (XFOR).
Website
https://www.x4pharma.comLocation
Boston, Massachusetts, USA
Founded
2015
Investors
1
Categories
biotech, oncology, rare-disease, immunology, public-company
Notes
X4 Pharmaceuticals is a biotechnology company developing treatments for rare diseases and cancers by targeting the CXCR4 pathway. The company is publicly traded on NASDAQ under the ticker symbol XFOR and is headquartered in Boston, Massachusetts.
CXCR4 is a chemokine receptor that plays a critical role in:
- Immune cell trafficking
- Stem cell homing
- Cancer metastasis
- Rare immunodeficiency disorders
X4's lead program, mavorixafor, is a small molecule CXCR4 antagonist being developed for:
- WHIM syndrome (a rare primary immunodeficiency)
- Severe congenital neutropenia
- Certain cancers
Team
- Paula Ragan, Ph.D. - President & Chief Executive Officer
- LinkedIn: linkedin.com/in/paularagan
Additional Research Findings
- NASDAQ: XFOR (publicly traded)
- Portfolio company of Polaris Partners
- CXCR4 pathway targeting
- Lead program: Mavorixafor
- WHIM syndrome and neutropenia focus
- Boston, Massachusetts headquarters
- Founded in 2015
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Polaris Partners | US | biotech-focused | - | 33 |